Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response in kidney transplant recipients on standard vs mycophenolic acid–sparing immunosuppression after ChAdOx1 + BNT162b2 vaccination
TCTR20220402001Recruiting
- Sponsor
- N/A
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Trial of ChAdOx1 nCoV-19, tozinameran and mycophenolic acid in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by N/A. Started Oct 2021; status: recruiting.
02
Drugs
ChAdOx1 nCoV-19tozinameranmycophenolic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220402001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220402001.